2b16: Difference between revisions
New page: left|200px<br /> <applet load="2b16" size="450" color="white" frame="true" align="right" spinBox="true" caption="2b16, resolution 1.75Å" /> '''The crystal structu... |
No edit summary |
||
Line 1: | Line 1: | ||
[[Image:2b16.gif|left|200px]]<br /> | [[Image:2b16.gif|left|200px]]<br /><applet load="2b16" size="350" color="white" frame="true" align="right" spinBox="true" | ||
<applet load="2b16" size=" | |||
caption="2b16, resolution 1.75Å" /> | caption="2b16, resolution 1.75Å" /> | ||
'''The crystal structure of 2,4-dinitrophenol in complex with the amyloidogenic variant Transthyretin Tyr78Phe'''<br /> | '''The crystal structure of 2,4-dinitrophenol in complex with the amyloidogenic variant Transthyretin Tyr78Phe'''<br /> | ||
==Overview== | ==Overview== | ||
Systemic deposition of transthyretin (TTR) amyloid fibrils is always | Systemic deposition of transthyretin (TTR) amyloid fibrils is always observed in familial amyloidotic polyneuropathy, senile systemic amyloidosis and familial amyloidotic cardiomyopathy patients. Destabilization of the molecule leads to a cascade of events which result in fibril formation. The destabilization of a native protein with consequent conformational changes appears to be a common link in several human amyloid diseases. Intensive research has been directed towards finding small molecules that could work as therapeutic agents for the prevention/inhibition of amyloid diseases through stabilization of the native fold of the potentially amyloidogenic protein. This work provides insight into the structural determinants of the highly stabilizing effects of 2,4-dinitrophenol on wild-type TTR. It is also shown that similar interactions are established between this molecule and two highly amyloidogenic TTR variants: TTR L55P and TTR Y78F. In the three crystal complexes, 2,4-dinitrophenol occupies the two hormone-binding sites of the TTR tetramer. As a result of 2,4-dinitrophenol binding, the two dimers in the TTR tetramer become closer, increasing the stability of the protein. The three-dimensional structures now determined allow a comprehensive description of key interactions between transthyretin and 2,4-dinitrophenol, a small compound that holds promise as a template for the design of a therapeutical drug for amyloid diseases. | ||
==Disease== | ==Disease== | ||
Line 11: | Line 10: | ||
==About this Structure== | ==About this Structure== | ||
2B16 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with DNF as [http://en.wikipedia.org/wiki/ligand ligand]. Full crystallographic information is available from [http:// | 2B16 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=DNF:'>DNF</scene> as [http://en.wikipedia.org/wiki/ligand ligand]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2B16 OCA]. | ||
==Reference== | ==Reference== | ||
Line 17: | Line 16: | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Single protein]] | [[Category: Single protein]] | ||
[[Category: Damas, A | [[Category: Damas, A M.]] | ||
[[Category: Morais-de-Sa, E.]] | [[Category: Morais-de-Sa, E.]] | ||
[[Category: Neto-Silva, R | [[Category: Neto-Silva, R M.]] | ||
[[Category: Pereira, P | [[Category: Pereira, P J.]] | ||
[[Category: Saraiva, M | [[Category: Saraiva, M J.]] | ||
[[Category: DNF]] | [[Category: DNF]] | ||
[[Category: 2]] | [[Category: 2]] | ||
Line 29: | Line 28: | ||
[[Category: transthyretin]] | [[Category: transthyretin]] | ||
''Page seeded by [http:// | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 16:33:06 2008'' |